Dosage and Administration
The normal dose is 1 capsule (30 mg) 2-3 times per day. The duration of a course of treatment can vary from 1 to 2 months. At the end of the course, take a break of 2 months. Then the course can be repeated.
The drug is considered quite safe, the only contraindication is renal failure. Main side effects include allergic reactions (itchy skin), headaches, insomnia and dyspepsia.
In case of overdose side effects may aggravate.
Contraindications to the drug are minimal. Noben® is well tolerated in a prolonged therapy which strengthens positive improvements in patients and is not addictive.
- During intense intellectual and mental stress.
- Noben® activates the work of cells, improving memory and attention; it contributes to a significant improvement in the emotional state, removes the feeling of chronic fatigue, and reduces the severity and frequency of headaches.
- Noben helps slow down the aging process, improve memory, attention and well-being.
- The active component of Noben® restores the energy level in the brain cells during high physical tension, which makes it possible to train longer and recover faster.
4 Weeks Course is 90 pills x 30mg - Save with the volume discount!
Noben is a modern neuroprotector with a universal mechanism of action. The active substance of the drug is idebenone. This is the only synthesized coenzyme responsible for the generation of energy in nerve cells. The active component of Noben was first synthesized in Japan, at the Asian pharmaceutical company Takeda Pharmaceutical, with the goal of treating Alzheimer's disease (memory loss). Then the research was continued by European pharmacists.
A number of researchers recommend idebenone (Noben®) therapy for the treatment of various neurological disorders due its nootropic pharmacology. Indeed, as a structural analogue of CoQ10, the drug was shown to improve cerebral blood flow and oxygen delivery to human brain. It improves metabolic processes; in particular, synthesis of glucose and adenosine triphosphate (ATP) and lactate elimination. Also, idebenone slows down the process of lipid peroxidation and protects membranes of neurons and mitochondria from damage.
The drug is effective in the treatment of the following conditions:
- Multi-infarct dementia;
- Complex therapy after a stroke;
- Alzheimer's disease;
- Cerebrovascular disease;
- In the treatment of the consequences of a traumatic brain injury;
- Comprehensive treatment of migraine.
In 2007, idebenone was described as an orphan drug for the treatment of Leber's hereditary optic neuropathy (LHON) and later approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of certain rare conditions.
- Gillis et al (1994) Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders https://www.ncbi.nlm.nih.gov/pubmed/7981485
- H Gutzmann, D Hadler (1998) Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study https://www.ncbi.nlm.nih.gov/pubmed/9850939
- Gutzmann et al (2002) Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study https://www.ncbi.nlm.nih.gov/pubmed/11819153
- Hausse et al (2002) Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia https://www.ncbi.nlm.nih.gov/pubmed/11907009
- Thai et al (2003) Idebenone treatment fails to slow cognitive decline in Alzheimer's disease https://www.ncbi.nlm.nih.gov/pubmed/14663031
- McDaniel et al (2005) Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone https://www.ncbi.nlm.nih.gov/pubmed/17129261
- Di Prospero et al (2007) Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial https://www.ncbi.nlm.nih.gov/pubmed/17826341
- Schulz et al (2009) Clinical experience with high-dose idebenone in Friedreich ataxia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277883/
- K Voronkova, M Meleshkov (2009) Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia https://www.ncbi.nlm.nih.gov/pubmed/19430983
- Klopstock et al (2011) A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170530/
- Gerhardt et al (2011) Idebenone and Resveratrol Extend Lifespan and Improve Motor Function of HtrA2 Knockout Mice https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242749/
- Klopstock et al (2013) Persistence of the treatment effect of idebenone in Leber’s hereditary optic neuropathy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572931/
- S Jaber, B Polster (2015) Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier? https://www.ncbi.nlm.nih.gov/pubmed/25262284
- Guan et al (2016) Idebenone Maintains Survival of Mutant Myocilin Cells by Inhibiting Apoptosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989434/
- K Lyseng-Williamson (2016) Idebenone: A Review in Leber's Hereditary Optic Neuropathy https://www.ncbi.nlm.nih.gov/pubmed/27071925
- Yu-Wai-Man et al (2017) Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644719/
- Montenegro et al (2018) Idebenone: Novel Strategies to Improve Its Systemic and Local Efficacy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853719/
- Tiefenbach et al (2018) Idebenone and coenzyme Q10 are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177011/